Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Biotest AG's share price for the quarter that ended in Mar. 2025 was €40.2. Biotest AG's Shares Outstanding (EOP) for the quarter that ended in Mar. 2025 was 39.6 Mil. Therefore, Biotest AG's market cap for the quarter that ended in Mar. 2025 was €1,590.8 Mil.
Biotest AG's quarterly market cap
declined
from Sep. 2024 (€1,630.3 Mil) to Dec. 2024 (€1,622.4 Mil) and
declined
from Dec. 2024 (€1,622.4 Mil) to Mar. 2025 (€1,590.8 Mil).
Biotest AG's annual market cap
declined
from Dec. 2022 (€1,693.6 Mil) to Dec. 2023 (€1,677.8 Mil) and
declined
from Dec. 2023 (€1,677.8 Mil) to Dec. 2024 (€1,622.4 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Biotest AG's Enterprise Value for Today is €1,269.1 Mil.
Biotest AG (HAM:BIO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Biotest AG Market Cap Related Terms
Biotest AG Market Cap Historical Data
* Premium members only.
The historical data trend for Biotest AG's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:BIO vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Biotest AG's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotest AG Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biotest AG's Market Cap distribution charts can be found below:
* The bar in red indicates where Biotest AG's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Biotest AG's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotest AG (HAM:BIO) has a Market Cap of €791.4 Mil as of Jul. 05, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Biotest AG and its competitors.
Is Biotest AG's Market Cap too high?
Biotest AG's current Market Cap is €791.4 Mil. Overall, Biotest AG has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Biotest AG's Market Cap compare to VRTX and REGN?
Biotest AG's Market Cap of €791.4 Mil can be compared against companies in the Biotechnology industry. The industry median Market Cap is 121.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.26, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Biotest AG and its competitors. For the Biotechnology industry, the median Market Cap is 121.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotest AG's current Market Cap is €791.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest AG stock overvalued right now?
Biotest AG (HAM:BIO) has a current Market Cap of €791.4 Mil. The current Market Cap is €791.4 Mil. Biotest AG's overall GF Score™ is 56/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Biotest AG (HAM:BIO), the current Market Cap is €791.4 Mil as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The company covers preclinical and clinical development of the preparations, plasma collection, production, as well as marketing and sales.
56GF Score
Get the complete analysis for HAM:BIO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BIO has been successfully added to your 
